Warning: Hawkins, Inc.
ePT--the Electronic Newsletter of Pharmaceutical Technology
FDA issued a Warning Letter from its Minneapolis District Office to Hawkins, Inc., part of a diversified chemical company and pharmaceutical repackager here.
Minneapolis, MN (Sept. 26)-United States Food and Drug Administration issued a Warning Letter (http://www.fda.gov/foi/warning_letters/g6022d.htm) from its Minneapolis District Office to Hawkins, Inc. (www.hawkinschemical.com), part of a diversified chemical company and pharmaceutical repackager here. The five-page warning, issued Sept. 8 and posted Sept. 26, cites the company for seven deviations from current good manufacturing process in the repackaging and relabeling of active pharmaceutical ingredients from outside suppliers.
The listed shortcomings include:
- Failure to demonstrate adequacy of re-test dating for 155 APIs repackaged for use by compounding pharmacies;
- Failure to include on the certificate of analysis the name and address of the laboratory that performed the analysis;
- Failure to periodically validate the supplier's certificate of analysis;
- Failure to audit contract laboratories performing acceptance analyses;
- Failure to maintain written procedures describing the responsibilities of the quality control unit.
- Failure to retain samples of each API processed in the facility.
- Failure to document that air-handling filters are changed according to standard operating procedures.
(The Warning did not include CFR section numbers with individual citations.)
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
